Clinical Monograph • Medically Reviewed
Norvasc
Amlodipine Besylate • Dihydropyridine Calcium Channel Blocker (CCB)
Clinical Overview: Peripheral arterial vasodilator that inhibits transmembrane influx of extracellular calcium ions into vascular smooth muscle and cardiac myocytes.
Therapeutic Indications & Pharmacodynamics
Amlodipine produces gradual peripheral arteriolar dilation, resulting in steady 24-hour reduction of systemic blood pressure and cardiac afterload without precipitous reflex adrenergic stimulation. Demonstrated clinical superiority in the ALLHAT trial for stroke and cardiovascular mortality prevention.
Clinical Indications
Essential systemic hypertension, chronic stable angina, vasospastic (Prinzmetal's) angina, angiographically documented coronary artery disease.
Contraindications & Precautions
Known hypersensitivity to dihydropyridines, severe aortic stenosis, severe hypotension.
Prescribing Profile
Available Strengths:
2.5mg, 5mg, 10mg
2.5mg, 5mg, 10mg
Elimination Half-Life:
30 to 50 hours (permits reliable once-daily dosing)
30 to 50 hours (permits reliable once-daily dosing)
Reviewing Physician:
Dr. Caroline Hernandez, MD
Dr. Caroline Hernandez, MD
Institutional Dosing Monograph